Company Filing History:
4 out of 1,187 
3 out of 2,119 
Years Active: 2019-2025
Title: Spotlight on Inventor John Friedewald
Introduction
John Friedewald is an accomplished inventor based in Chicago, IL (US) with a significant contribution to the field of medical research. With a keen focus on gene expression profiles associated with sub-clinical kidney transplant rejection, Friedewald's work has paved the way for advanced diagnostic and monitoring techniques.
Latest Patents
Friedewald holds one patent titled "Gene expression profiles associated with sub-clinical kidney transplant rejection." This groundbreaking patent involves a genome-wide gene analysis of expression profiles to identify molecular biomarkers associated with subclinical acute rejection. The identified gene sets offer valuable insights for the diagnosis, prognosis, and monitoring of subAR, revolutionizing the approach to kidney transplant rejection.
Career Highlights
Throughout his career, Friedewald has made significant contributions while working at prestigious institutions such as The Scripps Research Institute and Northwestern University. His expertise and dedication to medical research have been instrumental in advancing the understanding of subclinical acute rejection in kidney transplant patients.
Collaborations
During his professional journey, Friedewald had the privilege of collaborating with esteemed colleagues, including his coworker Daniel Salomon. Together, they have synergized their expertise to drive innovation in the field of gene expression analysis and its applications in kidney transplant research.
Conclusion
Inventor John Friedewald's pioneering work in gene expression profiles associated with sub-clinical kidney transplant rejection highlights his commitment to advancing medical science. His patent stands as a testament to his dedication to improving diagnostics and monitoring for subclinical acute rejection, ultimately enhancing patient outcomes in kidney transplant procedures.